CALABRESI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 506
EU - Europa 476
AS - Asia 79
AF - Africa 1
SA - Sud America 1
Totale 1.063
Nazione #
US - Stati Uniti d'America 505
PL - Polonia 220
IT - Italia 95
IE - Irlanda 44
SE - Svezia 35
CH - Svizzera 30
HK - Hong Kong 26
CN - Cina 21
DE - Germania 12
GB - Regno Unito 11
JO - Giordania 11
RU - Federazione Russa 11
SG - Singapore 10
FR - Francia 6
VN - Vietnam 6
BE - Belgio 4
FI - Finlandia 4
KR - Corea 4
ES - Italia 2
BR - Brasile 1
CA - Canada 1
IN - India 1
MU - Mauritius 1
NL - Olanda 1
UA - Ucraina 1
Totale 1.063
Città #
Warsaw 220
Fairfield 73
Chandler 52
Dublin 44
Ashburn 39
Woodbridge 37
Florence 36
Seattle 35
Houston 33
Ann Arbor 30
Cambridge 30
Bern 28
Wilmington 24
Hong Kong 18
Altamura 14
Lawrence 14
Princeton 11
Beijing 10
Bremen 10
Buffalo 9
Boston 8
Dong Ket 6
Kent 6
Moscow 6
New York 6
Dearborn 5
Brussels 4
Cagliari 4
San Diego 4
Seoul 4
Boardman 3
Hillsboro 3
Los Angeles 3
Redwood City 3
San Jose 3
Shanghai 3
Basel 2
Cantagallo 2
Cusano Milanino 2
Ealing 2
Falls Church 2
Fiesole 2
Kunming 2
Medford 2
Phoenix 2
Reston 2
Romainville 2
Seville 2
Andover 1
Augusta 1
Bethesda 1
Corato 1
Falkenstein 1
Fiumicino 1
Fontebuona 1
Jacksonville 1
Lappeenranta 1
Livorno 1
Monteroni D'arbia 1
Montreal 1
Nanchang 1
Noisy-le-sec 1
Pisa 1
Pune 1
Rome 1
Salerno 1
Scarperia e San Piero 1
Schiavon 1
Shenzhen 1
Signa 1
Singapore 1
São Paulo 1
Tappahannock 1
Wandsworth 1
Xian 1
Totale 889
Nome #
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 233
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 150
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 141
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 100
Characterization of novel molecular targets and mechanisms in Philadelphia-negative Myeloproliferative Neoplasms 96
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 84
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles 82
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 72
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs 46
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 33
The MPL mutation 24
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model 17
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 5
Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells 2
Totale 1.085
Categoria #
all - tutte 3.707
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.707


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020246 12 16 7 15 29 37 25 39 23 13 25 5
2020/2021156 9 23 4 20 11 16 8 10 15 23 7 10
2021/202270 1 2 8 0 2 4 0 7 5 6 14 21
2022/2023268 15 51 14 22 15 34 30 14 29 2 9 33
2023/2024132 2 15 15 5 12 16 1 37 4 5 13 7
2024/202512 12 0 0 0 0 0 0 0 0 0 0 0
Totale 1.085